Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 4 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thymoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Mesothelioma 1 Lung Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 6 Cisplatin 6 Nivolumab 5 Gemcitabine 5 Drug Therapy 5 Radiotherapy 4 Docetaxel 4 pembrolizumab 3 Platinum Compounds 3 Immune Checkpoint Inhibitors 3 Endostatins 3 Carboplatin 3 tislelizumab 2 endostar protein 2 durvalumab 2 camrelizumab 2 Thalidomide 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Gefitinib 2 Erlotinib Hydrochloride 2 Bevacizumab 2 Afatinib 2 trilaciclib 1 toripalimab 1 titanium silicide 1 osimertinib 1 olaparib 1 lorlatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Carcinoma, Non-Small-Cell Lung × olaparib × Clear all

NCT01788332 2018-10-26

PIN

Velindre NHS Trust

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡